On Nov. 13, 2017, the Department of Transportation (DOT) published a final rule that, among other items, expands DOT’s current drug testing panel to include certain semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone). Testing for methylenedioxyethylamphetamine (MDEA) has been removed while methylenedioxyamphetamine (MDA) has been added as an initial test analyte.
The final rule also clarifies existing drug testing program provisions and definitions, makes technical amendments and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens. The final rule becomes effective Jan. 1, 2018.
“The opioid crisis is a threat to public safety when it involves safety-sensitive employees involved in the operation of any kind of vehicle or transport,” said DOT Secretary Elaine L. Chao. “The ability to test for a broader range of opioids will advance transportation safety significantly and provide another deterrence to opioid abuse, which will better protect the public and ultimately save lives.”
Click here to read more from DOT.
Click here to read the final rule as published in the Federal Register.
Related News
- GP Coleman to SMART-TD NTS attendees: “We will fight for the membership”
- DOL memo states that TAB workers on Davis-Bacon projects are entitled to prevailing wage
- NTS Day 3: Railroad safety improvements driven by member reports
- NTS Day 3: America’s transit safer because of union member efforts
- TD NTS: STB chair and vice chair address officers, assure labor will have input
- TTD president: Labor needs to stick together to maintain progress
- TD National Training Seminar begins; officers train to confidently represent union members
- Local 435 lifts working conditions, pay and benefits in Gainesville
- Fourth of July 2024: General President Coleman’s message to members
- SMART-TD transit union conducts first Bus/Transit Day on the Hill